News

On December 6, 2023, Keller Rohrback partner David Ko was appointed to the Executive Committee for the Self-Funded Payer Track of the MDL In Re Insulin Pricing Litigation.  

Keller Rohrback was among the first firms in the Country to sue pharmacy benefit managers for conspiring with insulin manufacturers to drive up the cost of insulin for American consumers.  These abusive practices continue today, and they ...

Keller Rohrback is investigating a conspiracy to hike the price of the drug colchicine (brand name Colcrys), primarily used to treat gout.

Keller Rohrback is investigating reports that the manufacturer of the drug, Humira, has been using patent manipulation and other tactics to keep competitors out of the market for years in order to keep the price of its blockbuster drug ...

Keller Rohrback is investigating the high price of Nuvigil (generically known as armodafinil). Nuvigil is a critical medication used to reduce extreme sleepiness in sufferers of narcolepsy and other sleep-related disorders.

Keller Rohrback is honored to have been recognized by the American Antitrust Institute (AAI) for its work on the In re EpiPen Marketing, Sales Practices, and Antitrust Litigation.  The Keller Rohrback team of Lynn Sarko, Gretchen Freeman ...

  In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation United States District Court, District of Kansas MDL No. 2785   EpiPen Settlement Update.

Teva Pharmaceutical Industries (“Teva”), the maker of the multiple sclerosis drug Copaxone, allegedly boosted the drug’s price tag from $17,000 to $73,000 per year—turning an already pricy medication into a completely ...